A multicenter Phase III study of nomacopan for the treatment of moderate and severe bullous pemphigoid (BP) has been initiatedNomacopan has potential to replace …
PRESS RELEASES
Akari Therapeutics Announces Poster Presentation of Phase II Bullous Pemphigoid Disease and Phase III Trial Design at American Academy of Dermatology Association Virtual Meeting Experience
NEW YORK and LONDON, April 22, 2021 – Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceuticalcompany focused on innovative therapeutics to treat orphan …
Akari Therapeutics Reports Full Year 2020 Financial Results and Highlights Recent Clinical Progress
‒ Opening of Investigational New Drug Application (IND) with U.S. Food and Drug Administration (FDA) for Phase III study of nomacopan in bullous pemphigoid …
